These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. C3a expressed in the central nervous system protects against LPS-induced shock. Boos L; Szalai AJ; Barnum SR Neurosci Lett; 2005 Oct; 387(2):68-71. PubMed ID: 16085360 [TBL] [Abstract][Full Text] [Related]
30. 7th International Immunoglobulin Conference: Mechanisms of action. Basta M; Branch DR Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):87-8. PubMed ID: 25546774 [TBL] [Abstract][Full Text] [Related]
31. Protective role of hematopoietic prostaglandin D synthase in transient focal cerebral ischemia in mice. Liu M; Eguchi N; Yamasaki Y; Urade Y; Hattori N; Urabe T Neuroscience; 2009 Sep; 163(1):296-307. PubMed ID: 19531375 [TBL] [Abstract][Full Text] [Related]
32. High-dose intravenous immunoglobulin exerts neuroprotective effect in the rat model of neonatal asphyxia. Chen B; Yoon JS; Hu B; Basta M Pediatr Res; 2014 May; 75(5):612-7. PubMed ID: 24488088 [TBL] [Abstract][Full Text] [Related]
33. Phagocytosis of apoptotic inflammatory cells by microglia and its therapeutic implications: termination of CNS autoimmune inflammation and modulation by interferon-beta. Chan A; Seguin R; Magnus T; Papadimitriou C; Toyka KV; Antel JP; Gold R Glia; 2003 Sep; 43(3):231-42. PubMed ID: 12898702 [TBL] [Abstract][Full Text] [Related]
34. Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration. Williams AJ; Dave JR; Tortella FC Neurochem Int; 2006 Jul; 49(2):106-12. PubMed ID: 16759750 [TBL] [Abstract][Full Text] [Related]
35. Inflammatory mechanisms after ischemia and stroke. Danton GH; Dietrich WD J Neuropathol Exp Neurol; 2003 Feb; 62(2):127-36. PubMed ID: 12578222 [TBL] [Abstract][Full Text] [Related]
36. The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses. Peng Q; Li K; Sacks SH; Zhou W Inflamm Allergy Drug Targets; 2009 Jul; 8(3):236-46. PubMed ID: 19601884 [TBL] [Abstract][Full Text] [Related]
37. Injury site-specific targeting of complement inhibitors for treating stroke. Alawieh A; Tomlinson S Immunol Rev; 2016 Nov; 274(1):270-280. PubMed ID: 27782326 [TBL] [Abstract][Full Text] [Related]
38. MERS-CoV infection causes brain damage in human DPP4-transgenic mice through complement-mediated inflammation. Jiang Y; Chen Y; Sun H; Zhang X; He L; Li J; Zhao G; Sun S J Gen Virol; 2021 Oct; 102(10):. PubMed ID: 34704923 [TBL] [Abstract][Full Text] [Related]
39. The role of complement-derived mediators in inflammatory skin diseases. Tagami H Arch Dermatol Res; 1992; 284 Suppl 1():S2-9. PubMed ID: 1285651 [TBL] [Abstract][Full Text] [Related]
40. Role of complement systems in IVIG mediated attenuation of cognitive deterioration in Alzheimer's disease. Gong B; Levine S; Barnum SR; Pasinetti GM Curr Alzheimer Res; 2014; 11(7):637-44. PubMed ID: 25115545 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]